11 completed, 2 unknown, 1 recruiting, 1 terminated. 5 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Huntington Study Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Longitudinal Endpoint Assessment of Disease Burden in HD Huntington Disease | Recruiting | Huntington Study Group | 600 | 2024-06-25 | 2025-09-10 | |
| Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical Research Huntington Disease | Completed | Huntington Study Group | 131 | 2024-04-10 | 2025-12-23 | |
| Development of the Virtual Unified Huntington's Disease Rating Scale Huntington Disease | Completed | Huntington Study Group | 60 | 2022-09-22 | 2023-09-28 | |
| Making HD Voices Heard Huntington Disease | Completed | Huntington Study Group | 698 | 2022-03-23 | 2023-10-12 | |
| Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease Valbenazine - Chorea, Huntington | Phase 3 | Terminated | Neurocrine Biosciences | 154 | 2020-09-18 | 2026-11-03 |
| Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease Valbenazine, Placebo - Chorea, Huntington | Phase 3 | Completed | Neurocrine Biosciences | 128 | 2019-11-13 | 2023-10-11 |
| A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi VX15/2503, Placebo - Huntington's Disease | Phase 2 | Completed | Vaccinex Inc. | 301 | 2015-07-01 | 2022-05-02 |
| A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease Pridopidine, Placebo - Huntington's Disease | Phase 2 | Completed | Prilenia | 408 | 2014-02-28 | 2021-07-19 |
| A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease Memantine, Placebo - Huntington Disease | Phase 2 | Completed | University of British Columbia | 19 | 2011-09-01 | 2020-01-13 |
| Ursodiol in Huntington's Disease ursodiol, placebo - Huntington Disease | Phase 1 | Unknown | Oregon Health and Science University | 21 | 2007-08-01 | 2009-02-05 |
| A Study of the Novel Drug Dimebon in Patients With Huntington's Disease Placebo, Dimebon - Huntington's Disease | Phase 2 | Completed | Medivation, Inc. | 91 | 2007-07-01 | 2015-06-08 |
| Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease Dimebon - Huntington's Disease | Phase 1 / Phase 2 | Completed | Medivation, Inc. | 9 | 2006-10-01 | 2008-01-04 |
| Cooperative Huntington's Observational Research Trial Huntington Disease | Unknown | HP Therapeutics Foundation | 5000 | 2006-02-01 | 2011-03-07 | |
| TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease Ethyl-EPA (Miraxion™) - Huntington Disease | Phase 3 | Completed | Amarin Neuroscience Ltd | 300 | 2005-09-01 | 2007-12-27 |
| Prospective Huntington At Risk Observational Study Huntington Disease | Completed | Huntington Study Group | 1001 | 1999-07-09 | 2024-09-03 |
Huntington Disease (15) · Chorea (2) · Charcot-Marie-Tooth Disease, Axonal, Type 2A2 (1) · Lymphoma, Follicular (1) · Movement Disorders (1) · Prodromal Symptoms (1)
latrepirdine (2) · valbenazine (2) · Docosahexaenoic Acids (1) · Memantine (1) · Ursodeoxycholic Acid (1) · eicosapentaenoic acid ethyl ester (1) · pepinemab (1) · pridopidine (1)
United States (14) · Canada (8) · Australia (2) · Austria (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Russia (1) · United Kingdom (1)
Ira Shoulson, MD (2) · Amy Brown, MD, MS (1) · Andrew Feigin, MD (1) · Blair Leavitt, MD (1) · Blair R. Leavitt, MD,CM,FRCPC (1) · Christopher Ross, MD, PhD (1) · Ira Shoulson, M.D. (1) · Jamison Seabury (1) · Jody Goldstein (1) · Karen E Anderson, MD (1) · Karl D Kieburtz, MD (1) · Karl Kieburtz, MD, MPH (1) · Michael R. Hayden, MD,ChB,PhD (1) · Penelope Hogarth, M.D. (1)
PMID 18627059, PMID 19064745, PMID 20142523, PMID 22359536, PMID 24126537, PMID 30103342, PMID 30563778, PMID 30776019, PMID 31611263, PMID 32250312, PMID 35941373, PMID 36463457, PMID 36811812, PMID 37210099